Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial.

Antioxidants (Basel) · 2021 · PMC8389327 · PMID 34439518

Europe PMC DOI

hedged sentence

0.1010

closest p · 2.0× alpha

0.1010

boldest claim

The sentences

showed a trendp = 0.101not close (p > 0.1)

At the 60 mg/Kg/day dose, DFO showed a trend to reduce TSAT ( p = 0.101) after only 24 h of treatment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.